Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/V vs U/V in COPD Phenotypes
NCT05342558Phase 4Completed
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fluticasone propionate + vilanterol and Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Instituto Nacional de Enfermedades Respiratorias. Primary endpoints: Exacerbations rate at 24 weeks and Exacerbations free interval at 24 weeks. Started Sep 2017; status: completed.
02
Drugs
fluticasone propionate + vilanterolAnoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05342558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342558.